At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
FF-3 dry powder +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus
In Brief
A Phase 2 clinical trial evaluating FF-3 dry powder and Placebo for Influenza. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited Kingdom
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartSep 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedApr 22, 2015
Enrollment StartSep 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.2 years ago
Interventions
FF-3 dry powderdrug
FF-3 dry powder administered by nasal inhalation
Placebodrug
Placebo dry powder administered by nasal inhalation